Viewray VRAY Stock Price, Quote, News & Analysis

This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 . This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies. The company’s average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings. Zacks provides the average brokerage recommendation for thousands of stocks for most of the leading investment web sties.

It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. ViewRay reports Q4 EPS , consensus Reports Q4 revenue $34.7M, consensus $33.89M. ViewRay had total cash and cash equivalents of $142.5M at December 31,… In 2025, VRAY is forecast to generate -$38,179,122 in earnings, with the lowest earnings forecast at -$38,179,122 and the highest earnings forecast at -$38,179,122. If ViewRay Inc takes out the full calculated possible swing range there will be an estimated 9.54% move between the lowest and the highest trading price during the day. This stock may move much during the day and with a large prediction interval from the Bollinger Band this stock is considered to be “high risk”.

Analyst rating

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.52% per year.

Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence . Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Based on short-term price targets offered by seven analysts, the average price target for ViewRay comes to $7.14. The average price target represents an increase of 101.69% from the last closing price of $3.54. A price target is a stock market term used by investors and analysts to indicate the level at which they believe a stock will trade. The price target is based on several factors, including a company’s earnings, revenue, and valuation. Determining a price target can be tricky, as it is an estimate and not always accurate.

Growth & Valuation

According to undefined Wall Street analysts, ViewRay’s projected average quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VRAY previous annual EPS of $NaN . Based on 8 analysts giving stock ratings to VRAY in the past 3 months. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

The average price target for ViewRay is $6.25 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $4.00. This represents a potential 76.55% upside from VRAY’s last price of $3.54. In a report released today, Marie Thibault from BTIG reiterated a Buy rating on Viewray (VRAY – Research Report), with a price target of $7.00. The company’s shares closed yesterday at $4.45.According to TipRanks, Thibault… The best way to use analyst ratings is to supplement your investment research.

ViewRay started at buy with $7 stock price target at Stifel Nicolaus

According to 14 analysts, the average rating for VRAY stock is “Buy.” The 12-month stock price forecast is $7.27, which is an increase of 105.95% from the latest price. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. This estimation is based on a high estimate of $10.00 and a low estimate of $7.00. Even if you are not interested in VRAY stock, you should still be aware of its competitors.

• According to our research, VRAY stock is a very good long-term investment.
• (0.00%), Susquehanna International Group LLP (0.00%), Geode Capital Management LLC (1.50%) and Silverarc Capital Management LLC (1.33%).
• Tickergate does not bear any responsibility or any losses or damages that may occur as a result of reliance on this data.
• Analyst ratings can change quickly, and a rating that was accurate six months ago might not be relevant today.

Viewray reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.158. Following the earnings report the stock price went down -3.571%. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.158 by $0.008. linux for network engineers: practical linux with gns3 david bombal According to our research, VRAY stock is a very good long-term investment. VRAY share price has been in a bull cycle for the past year. Tickergate does not provide financial advices and does not issue recommendations or offers to buy stocks of sell any securities.

In the next year, analysts expect Free Cash Flow to reach $-72.36M – an increase of 13.68%. For the next nine years, the forecast is for Free Cash Flow to grow by 13.79%. ViewRay’s Price has grown in the last two years, jumping from $0.00 to $0.00 – an increase of 100.00%.

VRAY Overview

The ViewRay Inc stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $3.76 and $4.35. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Thursday, February 02, 2023, and so far it has fallen -25.63%.

ViewRay’s EPS has decreased In the last two years, from $-1.12 to $-0.67 – a 40.18% drop. In the next year, analysts predict that EPS will reach $-0.83 – an increase of 23.78%. For the next nine years, the forecast is for EPS to grow by 25.08%.

Please do not rely on them blindly; instead, use them as one tool in your decision-making process. Analyst ratings can change quickly, and a rating that was accurate six months ago might not be relevant today. Analyst ratings are recommendations made by various stock analysts. Public companies are rated by analysts who monitor their industries. These stock ratings result from a thorough evaluation of a traded company using known metrics such as sales, earnings, and potential catalysts.

About ViewRay Inc

ViewRay’s last stock rating was published by Piper Sandler on Aug 02, 2022. The company gave VRAY a “Overweight” rating, the same as its previous rate. The 8 analysts offering 1 year price forecasts for VRAY have a max estimate of — and a min estimate of —. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. High institutional ownership can be a signal of strong market trust in this company.

Firstly a stronger fallrate is indicated, but false breaks and “sell-off” may occur. However, a further fall is realistic and any reactions back to the breaking point ($3.81) are considered to be a “second chance” to get out. According to the fan-theory $3.12 will represent the new bottom line of the next trend, but it is far too early to say this for certain. Intraday Data provided by FACTSET and subject to terms of use.

ViewRay’s average quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VRAY’s average quarter net income forecast represents a NaN% decrease compared to the company’s last quarter net income of $NaN . ViewRay’s average annual net income forecast for undefined is $NaN, with a range of $NaN to $NaN.

Broker Rating

During the last day, the stock moved $0.135 between high and low, or 3.87%. For the last week, the stock has had daily average volatility of 6.45%. There is no support from accumulated volume below today’s level and given the right condition the stock may https://day-trading.info/ perform very badly in the next couple of days. World’s first MRIdian center at Barnes-Jewish Hospital continues to lead the way for advanced precision cancer therapy with MRI-guided radiation DENVER , March 2, 2023 /PRNewswire/ — ViewRay, Inc. (N…